141.78
  Price0.84%   +1.18
(Pre-market: .00 -141.78 -100.00%)
May-14-22 07:04AM 3 Dirt-Cheap Stocks You Can Buy Right NowThe Motley Fool
May-13-22 08:42AM The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven PharmaceuticalZacks Investment Research
May-12-22 09:11AM Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory NewsZacks Investment Research
May-11-22 02:12AM Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss WiderZacks Investment Research
10:02AM Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022Benzinga
May-10-22 04:48AM Dow books fourth straight day of losses as stocks end mixedMarketWatch
04:42AM Why Biohaven Pharmaceutical Stock Soared TodayThe Motley Fool
May-10-22 03:49AM Dow turns lower heading toward closing bell, while S&P 500, Nasdaq rise in choppy stock-market tradeMarketWatch
02:15AM 2 Extraordinary Events Sent These 2 Stocks Soaring TuesdayThe Motley Fool
May-10-22 11:53AM Dow erases 500-point rise as stock-market bounce gives wayMarketWatch
09:52AM Dow up more than 300 points as stocks bounce after 3-day selloffMarketWatch
May-10-22 09:27AM Here's a list of 50 companies that are well-armed to beat back inflationMarketWatch
09:23AM The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO LeavesBenzinga
May-10-22 08:09AM Here's a list of 50 companies that are well-armed to beat back inflationMarketWatch
08:05AM Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
May-06-22 09:18AM Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season?Zacks Investment Research
May-05-22 05:35AM OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
Apr-01-22 03:16AM Attention Biotech Investors: Mark Your Calendar For April PDUFA DatesBenzinga
Feb-28-22 10:04AM Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP NodZacks Investment Research
Feb-25-22 08:25AM Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research
Feb-20-22 08:06AM The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News FlowBenzinga
Feb-15-22 10:28AM Biohaven (BHVN) Migraine Drug Meets Study Goals in ChinaZacks Investment Research
Feb-12-22 06:30AM What to Expect From Biogen's $2.3 Billion Shopping SpreeThe Motley Fool
Feb-02-22 04:00AM Diversify Your Portfolio With a New Psychedelic Drug ETFZacks Investment Research
01:12AM New Psychedelics ETF Launches On NYSE ArcaBenzinga
Jan-29-22 11:07AM Is This a Smart Deal for Pfizer?The Motley Fool
Jan-06-22 08:24AM The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug SalesBenzinga
Dec-08-21 08:35AM Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & MoreZacks Investment Research
Dec-07-21 12:16PM Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in StudyZacks Investment Research
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Cap:    |  Volume (24h):